<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>METOCLOPRAMIDE HYDROCHLORIDEÂ - metoclopramide hydrochlorideÂ tablet, orally disintegratingÂ </strong><br>Novel Laboratories, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<br>These highlights do not include all the information needed to use METOCLOPRAMIDE hydrochloride safely and effectively. See full prescribing information for METOCLOPRAMIDE hydrochloride.<br><br>METOCLOPRAMIDE hydrochloride (Metoclopramide Hydrochloride) TABLET, ORALLY DISINTEGRATING for ORAL use.<br>Initial U.S. Approval: 1976</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold"> WARNING: <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">TARDIVE DYSKINESIA</span></span></h1>
<h1 class="Warning"><span class="Bold Italics"> See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold"> Treatment with metoclopramide can cause <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, a serious <span class="product-label-link" type="condition" conceptid="372604" conceptname="Movement disorder">movement disorder</span> that is often irreversible. The risk of developing <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> increases with the duration of treatment and the total cumulative dose.</span> </p>
<p class="Highlighta"><span class="Bold"> Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. There is no known treatment for <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.</span> </p>
<p class="Highlighta"> </p>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold"> WARNING: <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">TARDIVE DYSKINESIA</span></span></h1>
<h1 class="Warning"><span class="Bold Italics"> See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold"> Treatment with metoclopramide can cause <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, a serious <span class="product-label-link" type="condition" conceptid="372604" conceptname="Movement disorder">movement disorder</span> that is often irreversible. The risk of developing <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> increases with the duration of treatment and the total cumulative dose.</span> </p>
<p class="Highlighta"><span class="Bold"> Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. There is no known treatment for <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.</span> </p>
<p class="Highlighta"> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta"> Metoclopramide Orally Disintegrating Tablets are a dopamine receptor antagonist indicated for: </p>
<ul>
<li>
<span class="Bold"> Relief of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux</span>:</span> short-term (4 to 12 weeks) therapy for adults with symptomatic, documented <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span> who fail to respond to conventional therapy (<a href="#bc81311b-995d-4af1-b5f9-73b9e78dc22e">1.1</a>)</li>
<li>
<span class="Bold"> <span class="product-label-link" type="condition" conceptid="4142033" conceptname="Diabetic gastroparesis">Diabetic Gastroparesis</span> (Diabetic <span class="product-label-link" type="condition" conceptid="195847" conceptname="Gastroparesis syndrome">Gastric Stasis</span>):</span> the relief of symptoms in adults associated with acute and recurrent <span class="product-label-link" type="condition" conceptid="4142033" conceptname="Diabetic gastroparesis">diabetic gastroparesis</span> (<span class="product-label-link" type="condition" conceptid="195847" conceptname="Gastroparesis syndrome">gastric stasis</span>) (<a href="#baad875f-86a9-49e8-af10-3956b5ea1ef0">1.2</a>)</li>
</ul>
<p class="Highlighta"> Important Limitations: </p>
<ul>
<li> Therapy should not exceed 12 weeks in duration (<a href="#b77c18af-ff07-48b3-a512-ef5cae89ba19">1.3</a>)</li>
<li> Metoclopramide Hydrochloride Orally Disintegrating Tablets are recommended only for adults. The safety and effectiveness in pediatric patients have not been established (<a href="#b77c18af-ff07-48b3-a512-ef5cae89ba19">1.3</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>
<span class="Bold">Gastroesophageal Refulx Disease:</span> 10 mg to 15 mg dose up to four times daily at least 30 minutes before eating and at bedtime (<a href="#b48610ec-ede8-47d0-aefd-50d983a9316a">2.2</a>)</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4142033" conceptname="Diabetic gastroparesis">Diabetic Gastroparesis</span> (Diabetic <span class="product-label-link" type="condition" conceptid="195847" conceptname="Gastroparesis syndrome">Gastric Stasis</span>):</span> 10 mg dose four times daily at least 30 minutes before eating and at bedtime for two to eight weeks (<a href="#b124f385-2b11-4ee6-b7bf-0ecf6fdfb1ff">2.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta"> Orally Disintegrating Tablets: 5 mg and 10 mg (<a href="#b635ce04-144a-462a-bcdf-175053353bbf">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li> <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Intestinal Obstruction</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span>, or Perforation (<a href="#bd33ea3b-5a7d-44a4-99ed-02253f8cd664">4.1</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span> (<a href="#b50a40a5-9a4c-4e0d-9977-692f09ef0047">4.2</a>)</li>
<li> Known Sensitivity or Intolerance (<a href="#b6ac8357-0d60-461b-a186-3ef77b57f1c0">4.3</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> (<a href="#bcb75412-1e17-466d-ba97-405e4b96250b">4.4</a>)</li>
<li> Concomitant Medications with Extrapyramidal Reactions (<a href="#b7c77e13-63c5-4147-b770-17bfc3874940">4.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li> <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span> (<a href="#b1b755f1-974a-4b63-acb7-6e0978df78c5">5.1</a>)</li>
<li> Acute <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonic Reactions</span>, Drug-induced <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span> and Other <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span> (<a href="#ba2509aa-6714-460d-868f-75ad26764e72">5.2</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (<a href="#b07f7405-02c0-4ecd-8ccd-4e8aeb3aa2b8">5.3</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> (<a href="#bc732cb4-4b83-4e29-8b11-21dfceff70f8">5.4</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> (<a href="#bdabd0cd-4609-48f9-a729-ad524142dbeb">5.5</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmia</span> (<a href="#b2e36b67-3d6e-42c5-9d00-56b4a96b2e89">5.6</a>)</li>
<li> Withdrawal from Metoclopramide (<a href="#b154a61a-3ae8-47e9-9f7e-0eec09e66c74">5.7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"> The most common adverse reactions (&gt;2%) are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (<a href="#b4e06bc6-d1b7-4ca0-818a-88f97c2b0f27">6.1</a>). </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Novel Laboratories, Inc. at 1-866-403-7592 or FDA at 1-800-FDA-1088 or <span class="Bold Italics">www.fda.gov/medwatch.</span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>
<span class="Underline"> Anticholinergic drugs</span>: Antagonize effects of metoclopramide (<a href="#bd8dd417-8ca1-4e71-acc1-b11606c15f6b">7.1</a>)</li>
<li>
<span class="Underline"> Narcotic analgesic drugs</span>: May increase sedation (<a href="#bd8dd417-8ca1-4e71-acc1-b11606c15f6b">7.1</a>)</li>
<li>
<span class="Underline"> Monoamine oxidase inhibitors</span>: May cause <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span> (due to catecholamine release) (<a href="#b54eabae-27bd-4b39-8473-45e0db38c7f3">7.2</a>)</li>
<li>
<span class="Underline"> Altered drug absorption</span>: May decrease absorption of drugs from the stomach and increase absorption of drugs from the small bowel (<a href="#b62e1014-59ad-46e9-bf9d-e44956a52a6c">7.3</a>)</li>
<li>
<span class="Underline"> Insulin</span>: Changes in food transit time may require adjustment of insulin dose or timing to avoid <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (<a href="#b72733d6-624f-4b49-8323-6d4bb402780a">7.4</a>)</li>
<li>
<span class="Underline"> Antidepressants, Antipsychotics, and Neuroleptics</span>: Concomitant use with metoclopramide is associated with increased risk of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> and <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (<a href="#bec5902b-3504-4335-9fc1-67b48632afbf">7.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>
<span class="Underline"> Pediatric Use</span>: The safety and effectiveness of Metoclopramide Hydrochloride Orally Disintegrating Tablets in pediatric patients have not been established (<a href="#ba3e9d3a-79e6-41e5-b58e-14d5bbf418c5">8.4</a>)</li>
<li>
<span class="Underline"> Geriatric Use</span>: Elderly patients may be more sensitive to adverse reactions such as sedation and drug-induced <span class="product-label-link" type="condition" conceptid="372604" conceptname="Movement disorder">movement disorders</span>. (<a href="#b6750a90-0c93-461a-96f0-95e9fff34c04">8.5</a>)</li>
<li>
<span class="Underline"> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span>: Initial dosing may need to be reduced and titrated (<a href="#bf00df90-aa3f-4c27-935a-8329ab593f8a">8.6</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 12/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">TARDIVE DYSKINESIA</span>
</span></a></h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1Â  INDICATIONS &amp; USAGE
</span></a></h1>
<h2><a href="#section-1.1" class="toc"><span class="Bold">1.1 Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span>
</span></a></h2>
<h2><a href="#section-1.2" class="toc"><span class="Bold">1.2 <span class="product-label-link" type="condition" conceptid="4142033" conceptname="Diabetic gastroparesis">Diabetic Gastroparesis</span> (Diabetic <span class="product-label-link" type="condition" conceptid="195847" conceptname="Gastroparesis syndrome">Gastric Stasis</span>)
</span></a></h2>
<h2><a href="#section-1.3" class="toc"><span class="Bold">1.3 Important Limitations
</span></a></h2>
<h1><a href="#section-2" class="toc"><span class="Bold"> 2Â  DOSAGE AND ADMINISTRATION
</span></a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1 Important Instructions for Use
</span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold">2.2 Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span>
</span></a></h2>
<h2><a href="#section-2.3" class="toc"><span class="Bold">2.3 <span class="product-label-link" type="condition" conceptid="4142033" conceptname="Diabetic gastroparesis">Diabetic Gastroparesis</span> (Diabetic <span class="product-label-link" type="condition" conceptid="195847" conceptname="Gastroparesis syndrome">Gastric Stasis</span>)
</span></a></h2>
<h2><a href="#section-2.4" class="toc"><span class="Bold">2.4 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</span></a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3Â  DOSAGE FORMS &amp; STRENGTHS
</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4Â  CONTRAINDICATIONS
</span></a></h1>
<h2><a href="#section-4.1" class="toc"><span class="Bold">4.1 <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Intestinal Obstruction</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span>, or Perforation
</span></a></h2>
<h2><a href="#section-4.2" class="toc"><span class="Bold">4.2 <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span>
</span></a></h2>
<h2><a href="#section-4.3" class="toc"><span class="Bold">4.3 Known Sensitivity or Intolerance
</span></a></h2>
<h2><a href="#section-4.4" class="toc"><span class="Bold">4.4 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span>
</span></a></h2>
<h2><a href="#section-4.5" class="toc"><span class="Bold">4.5 Concomitant Medications with Extrapyramidal Reactions
</span></a></h2>
<h1><a href="#section-5" class="toc"><span class="Bold"> 5Â  WARNINGS AND PRECAUTIONS 
</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1 <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span>
</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2 Acute <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonic Reactions</span>, Drug-induced <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span>, and Other <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span>
</span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3 <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span>
</span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>
</span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold">5.5 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold">5.6 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmia</span>
</span></a></h2>
<h2><a href="#section-5.7" class="toc"><span class="Bold">5.7 Withdrawal from Metoclopramide
</span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold"> 6Â  ADVERSE REACTIONS
</span></a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1 Clinical Trials Experience
</span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">6.2 Post-Marketing Experience
</span></a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7Â  DRUG INTERACTIONS 
</span></a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold">7.1 Anticholinergic and Narcotic Analgesic Drugs
</span></a></h2>
<h2><a href="#section-7.2" class="toc"><span class="Bold">7.2 Monoamine Oxidase Inhibitors
</span></a></h2>
<h2><a href="#section-7.3" class="toc"><span class="Bold">7.3 Drug Absorption
</span></a></h2>
<h2><a href="#section-7.4" class="toc"><span class="Bold">7.4 Insulin
</span></a></h2>
<h2><a href="#section-7.5" class="toc"><span class="Bold">7.5 Antidepressants, Antipsychotics, and Neuroleptics
</span></a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold"> 8Â  USE IN SPECIFIC POPULATIONS 
</span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold">8.1Â  Pregnancy
</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold">8.2 Labor and Delivery
</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold">8.3 Nursing Mothers
</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.4 Pediatric Use
</span></a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold">8.5 Geriatric Use
</span></a></h2>
<h2><a href="#section-8.6" class="toc"><span class="Bold">8.6 Other Special Populations
</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10Â  OVERDOSAGE 
</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11Â  DESCRIPTION 
</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12Â  CLINICAL PHARMACOLOGY 
</span></a></h1>
<h2><a href="#section-11.1" class="toc"><span class="Bold">12.1 Mechanism of Action
</span></a></h2>
<h2><a href="#section-11.2" class="toc"><span class="Bold">12.2 Pharmacodynamics
</span></a></h2>
<h2><a href="#section-11.3" class="toc"><span class="Bold">12.3 Pharmacokinetics
</span></a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13Â  NONCLINICAL TOXICOLOGY 
</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">16 HOW SUPPLIED/STORAGE AND HANDLING
</span></a></h1>
<h1><a href="#section-14" class="toc"><span class="Bold">17Â  PATIENT COUNSELING INFORMATION
</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="b7ff1afe-207b-4a7b-bda9-ebfee20bf0f8"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">TARDIVE DYSKINESIA</span>
</span></h1>
<p class="First"></p>
<p></p>
<p></p>
<p></p>
<p></p>
<p><span class="Bold">Treatment with metoclopramide can cause <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, a serious <span class="product-label-link" type="condition" conceptid="372604" conceptname="Movement disorder">movement disorder</span> that is often irreversible. The risk of developing <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> increases with the duration of treatment and the total cumulative dose.</span></p>
<p><span class="Bold">Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. There is no known treatment for <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.</span></p>
<p><span class="Bold">Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. </span><span class="Bold"><br></span><span class="Bold">[See </span><a href="#b1b755f1-974a-4b63-acb7-6e0978df78c5">Warnings and Precautions (5.1)</a><span class="Bold">]</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1><span class="Bold">1Â  INDICATIONS &amp; USAGE
</span></h1>
<p class="First"></p>
<p></p>
<div class="Section">
<a name="bc81311b-995d-4af1-b5f9-73b9e78dc22e"></a><a name="section-1.1"></a><p></p>
<h2><span class="Bold">1.1 Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span>
</span></h2>
<p class="First">Metoclopramide Hydrochloride Orally Disintegrating Tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) who fail to respond to conventional therapy.</p>
</div>
<div class="Section">
<a name="baad875f-86a9-49e8-af10-3956b5ea1ef0"></a><a name="section-1.2"></a><p></p>
<h2><span class="Bold">1.2 <span class="product-label-link" type="condition" conceptid="4142033" conceptname="Diabetic gastroparesis">Diabetic Gastroparesis</span> (Diabetic <span class="product-label-link" type="condition" conceptid="195847" conceptname="Gastroparesis syndrome">Gastric Stasis</span>)
</span></h2>
<p class="First">Metoclopramide Hydrochloride Orally Disintegrating Tablets are indicated for the relief of symptoms associated with acute and recurrent <span class="product-label-link" type="condition" conceptid="4142033" conceptname="Diabetic gastroparesis">diabetic gastroparesis</span> (<span class="product-label-link" type="condition" conceptid="195847" conceptname="Gastroparesis syndrome">gastric stasis</span>) in adults.</p>
</div>
<div class="Section">
<a name="b77c18af-ff07-48b3-a512-ef5cae89ba19"></a><a name="section-1.3"></a><p></p>
<h2><span class="Bold">1.3 Important Limitations
</span></h2>
<p class="First">Metoclopramide Hydrochloride Orally Disintegrating Tablets are indicated for adults only. Therapy should not exceed 12 weeks in duration. The safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1><span class="Bold"> 2Â  DOSAGE AND ADMINISTRATION
</span></h1>
<div class="Section">
<a name="section-2.1"></a><p></p>
<h2><span class="Bold">2.1 Important Instructions for Use
</span></h2>
<p class="First">Take on an empty stomach at least 30 minutes before eating since food can decrease the peak concentrations of drug in the bloodstream and/or the time it takes to achieve the maximum drug level in the bloodstream [see <a href="#b07d20d6-23ef-4402-95d4-adb7f0dc21dd">Clinical Pharmacology (12.3)</a>]. Do not repeat dose if inadvertently taken with food.</p>
<p>Since the tablet absorbs moisture rapidly, only remove each dose from the packaging just prior to taking. Handle the tablet with dry hands and place on the tongue. If the tablet should break or crumble while handling, discard and remove a new tablet.</p>
<p>Metoclopramide Hydrochloride Orally Disintegrating Tablet disintegrates on the tongue in approximately one minute (with a range of 10 seconds to 14 minutes). Metoclopramide Hydrochloride Orally Disintegrating Tablet is designed to be taken without liquid; however, the effect on the pharmacokinetics of Metoclopramide Hydrochloride Orally Disintegrating Tablets taken with liquid is unknown.</p>
</div>
<div class="Section">
<a name="b48610ec-ede8-47d0-aefd-50d983a9316a"></a><a name="section-2.2"></a><p></p>
<h2><span class="Bold">2.2 Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span>
</span></h2>
<p class="First">For the relief of symptomatic, documented <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>), therapy should not exceed 12 weeks in duration.</p>
<p>Take 10 mg to 15 mg dose of Metoclopramide Hydrochloride Orally Disintegrating Tablets up to four times daily (e.g., at least 30 minutes before each meal and at bedtime). Doses may vary depending upon the symptoms being treated and the clinical response. If symptoms only occur intermittently or at specific times of the day, metoclopramide may be used in single doses up to 20 mg prior to the symptoms rather than continuous treatment.</p>
<p>Since there is a poor correlation between symptomatic relief and healing of esophageal lesions, any therapy directed at esophageal lesions is best confirmed by endoscopic evaluation. Although experience with the effects of metoclopramide on <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">esophageal erosions</span> and ulcerations is limited, healing was documented in a controlled trial using four times daily therapy at 15 mg/dose. Prolonged treatment (&gt;12 weeks) with metoclopramide should be avoided in all but rare cases where therapeutic benefit is thought to counterbalance the risks to the patient of developing <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. [see <a href="#b1b755f1-974a-4b63-acb7-6e0978df78c5">Warnings and Precautions (5.1)</a>]</p>
</div>
<div class="Section">
<a name="b124f385-2b11-4ee6-b7bf-0ecf6fdfb1ff"></a><a name="section-2.3"></a><p></p>
<h2><span class="Bold">2.3 <span class="product-label-link" type="condition" conceptid="4142033" conceptname="Diabetic gastroparesis">Diabetic Gastroparesis</span> (Diabetic <span class="product-label-link" type="condition" conceptid="195847" conceptname="Gastroparesis syndrome">Gastric Stasis</span>)
</span></h2>
<p class="First">For the relief of symptoms associated with <span class="product-label-link" type="condition" conceptid="4142033" conceptname="Diabetic gastroparesis">diabetic gastroparesis</span> (diabetic <span class="product-label-link" type="condition" conceptid="195847" conceptname="Gastroparesis syndrome">gastric stasis</span>), therapy of two to eight weeks is recommended. Therapy should not exceed 12 weeks in duration.</p>
<p>Take a 10 mg dose of Metoclopramide Hydrochloride Orally Disintegrating Tablets up to four times a day (e.g., at least 30 minutes before each meal and at bedtime).</p>
<p>The initial route of administration should be determined by the severity of the presenting symptoms. If only the earliest manifestations of diabetic <span class="product-label-link" type="condition" conceptid="195847" conceptname="Gastroparesis syndrome">gastric stasis</span> are present, oral administration of Metoclopramide Hydrochloride Orally Disintegrating Tablets may be initiated. However, if severe symptoms are present, therapy should begin with metoclopramide injection.</p>
<p>Administration of metoclopramide injection up to 10 days may be required before symptoms subside, at which time oral administration may be instituted. Since diabetic <span class="product-label-link" type="condition" conceptid="195847" conceptname="Gastroparesis syndrome">gastric stasis</span> is frequently recurrent, Metoclopramide Hydrochloride Orally Disintegrating Tablets therapy should be reinstituted at the earliest manifestation.</p>
</div>
<div class="Section">
<a name="section-2.4"></a><p></p>
<h2><span class="Bold">2.4 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</span></h2>
<p class="First">Some patients, such as the elderly or those with impaired kidney function (creatinine clearance below 40 mL/min) may be more sensitive to the therapeutic dose or the adverse effects of metoclopramide. Therefore, these patients should start therapy at a lower dose (approximately half the recommended dosage) and the dose should be titrated according to their overall clinical response and/or adverse event profile. Dialysis is not likely to be an effective method of drug removal in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> situations.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="b635ce04-144a-462a-bcdf-175053353bbf"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">3Â  DOSAGE FORMS &amp; STRENGTHS
</span></h1>
<p class="First"></p>
<p>5 mg Tablets: Metoclopramide Hydrochloride Orally Disintegrating Tablets are round, white to off-white, flat faced beveled edge tablet, debossed with â€˜Nâ€™ on one side and â€œ581â€? on the other side.</p>
<p>10 mg Tablets: Metoclopramide Hydrochloride Orally Disintegrating Tablets are round, white to off-white, flat faced beveled edge tablet, debossed with â€˜Nâ€™ on one side and â€œ580â€? on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1><span class="Bold">4Â  CONTRAINDICATIONS
</span></h1>
<div class="Section">
<a name="bd33ea3b-5a7d-44a4-99ed-02253f8cd664"></a><a name="section-4.1"></a><p></p>
<h2><span class="Bold">4.1 <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Intestinal Obstruction</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span>, or Perforation
</span></h2>
<p class="First">Do not use metoclopramide whenever stimulation of gastrointestinal motility may be dangerous such as in the presence of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, mechanical obstruction, or perforation.</p>
</div>
<div class="Section">
<a name="b50a40a5-9a4c-4e0d-9977-692f09ef0047"></a><a name="section-4.2"></a><p></p>
<h2><span class="Bold">4.2 <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span>
</span></h2>
<p class="First">Metoclopramide is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> because the drug may precipitate a <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>, most likely due to release of catecholamines from the tumor. Such hypertensive crises may be controlled by phentolamine.</p>
</div>
<div class="Section">
<a name="b6ac8357-0d60-461b-a186-3ef77b57f1c0"></a><a name="section-4.3"></a><p></p>
<h2><span class="Bold">4.3 Known Sensitivity or Intolerance
</span></h2>
<p class="First">Metoclopramide is contraindicated in patients with known sensitivity or intolerance to the drug.</p>
</div>
<div class="Section">
<a name="bcb75412-1e17-466d-ba97-405e4b96250b"></a><a name="section-4.4"></a><p></p>
<h2><span class="Bold">4.4 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span>
</span></h2>
<p class="First">Do not use metoclopramide in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> since the frequency and severity of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> may be increased.</p>
</div>
<div class="Section">
<a name="b7c77e13-63c5-4147-b770-17bfc3874940"></a><a name="section-4.5"></a><p></p>
<h2><span class="Bold">4.5 Concomitant Medications with Extrapyramidal Reactions
</span></h2>
<p class="First">Do not use metoclopramide in patients receiving other drugs which are likely to cause extrapyramidal reactions, since the frequency and severity of extrapyramidal reactions may be increased [see <a href="#ba2509aa-6714-460d-868f-75ad26764e72">Warnings and Precautions (5.2)</a>, <a href="#bf0ec9b7-d841-45aa-b9d0-45038b6d6837">Adverse Reactions (6.2)</a> and <a href="#bec5902b-3504-4335-9fc1-67b48632afbf">Drug Interactions (7.5)</a>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1><span class="Bold"> 5Â  WARNINGS AND PRECAUTIONS 
</span></h1>
<div class="Section">
<a name="b1b755f1-974a-4b63-acb7-6e0978df78c5"></a><a name="section-5.1"></a><p></p>
<h2><span class="Bold">5.1 <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span>
</span></h2>
<p class="First">[see <a href="#b7ff1afe-207b-4a7b-bda9-ebfee20bf0f8">Boxed Warning</a>]</p>
<p>Treatment with metoclopramide can cause <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> (TD), a potentially irreversible and disfiguring disorder characterized by involuntary movements of the face, tongue, or extremities. The risk of developing <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> increases with the duration of treatment and the total cumulative dose. An analysis of utilization patterns showed that about 20% of patients who used metoclopramide took it for longer than 12 weeks. Treatment with metoclopramide for longer than the recommended 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing TD.</p>
<p>Although the risk of developing TD in the general population may be increased among the elderly, women, and diabetics, it is not possible to predict which patients will develop metoclopramide-induced TD. Both the risk of developing TD and the likelihood that TD will become irreversible increase with duration of treatment and total cumulative dose.</p>
<p>Metoclopramide should be discontinued in patients who develop signs or symptoms of TD. There is no known effective treatment for established cases of TD, although in some patients, TD may remit, partially or completely, within several weeks to months after metoclopramide is withdrawn.</p>
<p>Metoclopramide itself may suppress, or partially suppress, the signs of TD, thereby masking the underlying disease process. The effect of this symptomatic suppression upon the long-term course of TD is unknown. Therefore, metoclopramide should not be used for the symptomatic control of TD.</p>
</div>
<div class="Section">
<a name="ba2509aa-6714-460d-868f-75ad26764e72"></a><a name="section-5.2"></a><p></p>
<h2><span class="Bold">5.2 Acute <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonic Reactions</span>, Drug-induced <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span>, and Other <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span>
</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal symptoms</span> (EPS), manifested primarily as acute <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reactions</span>, occur in approximately 1 in 500 patients treated with the usual adult dosages of 30 to 40 mg/day of metoclopramide. These usually are seen during the first 24 to 48 hours of treatment with metoclopramide, occur more frequently in pediatric patients and adult patients less than 30 years of age and are even more frequent at higher doses. These symptoms may include involuntary movements of limbs and facial <span class="product-label-link" type="condition" conceptid="4221082" conceptname="Grimaces">grimacing</span>, <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>, <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>, rhythmic protrusion of tongue, bulbar type of speech, <span class="product-label-link" type="condition" conceptid="4339090" conceptname="Trismus">trismus</span>, or <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reactions</span> resembling <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>. Rarely, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reactions</span> may present as <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span> and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, possibly due to <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>. If these symptoms occur, inject 50 mg diphenhydramine hydrochloride intramuscularly. Benztropine mesylate, 1 to 2 mg intramuscularly, may also be used to reverse these reactions.</p>
<p>Drug-induced <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span> can occur during metoclopramide therapy, more commonly within the first 6 months after beginning treatment, but also after longer periods. Parkinsonian symptoms generally subside within 2 to 3 months following discontinuation of metoclopramide. Patients with a history of Parkinsonâ€™s disease should be given metoclopramide cautiously, if at all, since such patients can experience exacerbation of Parkinsonian symptoms when taking metoclopramide.</p>
</div>
<div class="Section">
<a name="b07f7405-02c0-4ecd-8ccd-4e8aeb3aa2b8"></a><a name="section-5.3"></a><p></p>
<h2><span class="Bold">5.3 <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span>
</span></h2>
<p class="First">There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) associated with metoclopramide. Clinical manifestations of NMS include <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered consciousness, and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>). The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span> and primary central nervous system (CNS) pathology. The management of NMS should include immediate discontinuation of metoclopramide and other drugs not essential to concurrent therapy; intensive symptomatic treatment and medical monitoring; and, treatment of any concomitant serious medical problems for which specific treatments are available. Bromocriptine and dantrolene sodium have been used in treatment of NMS, but their effectiveness has not been established [see <a href="#b76246e4-6c2b-477a-bfb6-2fd696a7874b">Adverse Reactions (6)</a>].</p>
</div>
<div class="Section">
<a name="bc732cb4-4b83-4e29-8b11-21dfceff70f8"></a><a name="section-5.4"></a><p></p>
<h2><span class="Bold">5.4 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>
</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> associated with metoclopramide use has occurred in patients with and without a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Symptoms ranged from mild to severe and included <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. For those patients with a prior history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, metoclopramide should only be given if the expected benefits outweigh the potential risks.</p>
</div>
<div class="Section">
<a name="bdabd0cd-4609-48f9-a729-ad524142dbeb"></a><a name="section-5.5"></a><p></p>
<h2><span class="Bold">5.5 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</span></h2>
<p class="First">In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, caution should be exercised when metoclopramide is used in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. There are also clinical reports of hypertensive crises in some patients with undiagnosed <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>, thus any rapid <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span> associated with Metoclopramide Hydrochloride Orally Disintegrating Tablets use should result in immediate cessation of metoclopramide use in those patients [see <a href="#b50a40a5-9a4c-4e0d-9977-692f09ef0047">Contraindications (4.2)</a>].</p>
</div>
<div class="Section">
<a name="b2e36b67-3d6e-42c5-9d00-56b4a96b2e89"></a><a name="section-5.6"></a><p></p>
<h2><span class="Bold">5.6 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmia</span>
</span></h2>
<p class="First">Since metoclopramide produces a transient increase in plasma aldosterone, patients with cirrhosis or <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> may be at risk of developing <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> and volume overload. If these side effects occur at any time in any patients during metoclopramide therapy, the drug should be discontinued.</p>
</div>
<div class="Section">
<a name="b154a61a-3ae8-47e9-9f7e-0eec09e66c74"></a><a name="section-5.7"></a><p></p>
<h2><span class="Bold">5.7 Withdrawal from Metoclopramide
</span></h2>
<p class="First">Adverse reactions, especially those involving the nervous system, may occur after stopping the use of Metoclopramide Hydrochloride Orally Disintegrating Tablets. A small number of patients may experience withdrawal symptoms after stopping that could include <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, and/or <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>.</p>
<p><span class="Bold">Phenylketonurics:</span></p>
<p>Phenylalanine is a component of aspartame. Each 5 mg and 10 mg Metoclopramide Hydrochloride Orally Disintegrating Tablets contains 4.7 mg of phenylalanine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="b76246e4-6c2b-477a-bfb6-2fd696a7874b"></a><a name="section-6"></a><p></p>
<h1><span class="Bold"> 6Â  ADVERSE REACTIONS
</span></h1>
<p class="First"></p>
<div class="Section">
<a name="b4e06bc6-d1b7-4ca0-818a-88f97c2b0f27"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">6.1 Clinical Trials Experience
</span></h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.</p>
<p>A total of 86 subjects entered three studies with Metoclopramide Hydrochloride Orally Disintegrating Tablets; 12 subjects entered a pilot bioavailability study (BA); 44 subjects entered a bioequivalence (BE) study, and 30 subjects entered a food-effect study. The adverse reactions from the BE and food-effect study are summarized in Table 1. The pilot BA study data are not included because it was performed with a formulation different from the Metoclopramide Hydrochloride Orally Disintegrating Tablets formulation.</p>
<p>The adverse experience profile seen with Metoclopramide Hydrochloride Orally Disintegrating Tablets was similar to metoclopramide tablets. Thirty-three (33) adverse reactions were reported after receiving Metoclopramide Hydrochloride Orally Disintegrating Tablets and 30 adverse reactions were reported after receiving metoclopramide tablets.</p>
<p>Table 1: Adverse Reactions in BE and Food-Effect Study in â‰¥ 2% of Subjects</p>
<table frame="void" width="638">
<thead><tr class="First Last">
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="Bold"> Adverse Reaction</span></td>
<td class="BotruleLruleRruleToprule" align="left" valign="top">
<span class="Bold">Metoclopramide Hydrochloride Orally Disintegrating TabletsN</span><span class="Bold"><span class="Sup">1,3 </span></span><span class="Bold">(%)</span><span class="Bold"><span class="Sup">2</span></span>
</td>
<td class="BotruleLruleRruleToprule" align="left" valign="top">
<span class="Bold">Metoclopramide tabletsN</span><span class="Bold"><span class="Sup">1,4 </span></span><span class="Bold">(%)</span><span class="Bold"><span class="Sup">2</span></span>
</td>
</tr></thead>
<tfoot><tr class="First Last"><td class="BotruleLruleRruleToprule" align="left" colspan="3" valign="top">
<span class="Sup">1</span> N = number of subjects that reported adverse reactions<br><span class="Sup">2</span> Percent (%) occurrence = N divided by number of subjects dosed with respective study drug 3<span class="Sup"> N</span>umber of subjects dosed with Metoclopramide Hydrochloride Orally Disintegrating Tablets: 68 under fasted conditions and 28 under fed conditions.<br>4<span class="Sup"> N</span>umber of subjects dosed with metoclopramide tablets: 28 under fed conditions and 44 under fasted conditions.Â  </td></tr></tfoot>
<tbody>
<tr class="First">
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">4 (4.2 %)</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">4 (5.6 %)</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">2 (2.1 %)</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">1 (1.4 %)</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">2 (2.1 %)</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">2 (2.8 %)</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">5 (5.2 %)</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">3 (4.2 %)</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">2 (2.1 %)</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">2 (2.8 %)</td>
</tr>
<tr class="Last">
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">1 (1.0 %)</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">3 (4.2 %)</td>
</tr>
</tbody>
</table>
<p>The most frequently reported adverse reactions (greater than 2%) associated with Metoclopramide Hydrochloride Orally Disintegrating Tablets were: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. The most frequently reported adverse reactions (greater than 2%) associated with metoclopramide tablets were: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. The combined data from the fasted BE study and the food-effect study did not demonstrate any significant differences in the adverse event profile for Metoclopramide Hydrochloride Orally Disintegrating Tablets compared to metoclopramide tablets.</p>
</div>
<div class="Section">
<a name="bf0ec9b7-d841-45aa-b9d0-45038b6d6837"></a><a name="section-6.2"></a><p></p>
<h2><span class="Bold">6.2 Post-Marketing Experience
</span></h2>
<p class="First">The following adverse reactions are from the cumulative post-marketing experience with metoclopramide tablets. Since the reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>CNS Effects: <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span> occur in approximately 10% of patients receiving the most commonly prescribed dosage of 10 mg four times a day. <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> with <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> occurs less frequently. The incidence of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> is greater at higher doses. There are isolated reports of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> without clear-cut relationship to metoclopramide. Rarely, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> have been reported.</p>
<p><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Syndromes</span> (EPS):<br>Acute <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reactions</span>, the most common type of EPS associated with metoclopramide, occur in approximately 0.2% of patients (1 in 500) treated with 30 to 40 mg of metoclopramide per day. Symptoms include involuntary movements of limbs, facial <span class="product-label-link" type="condition" conceptid="4221082" conceptname="Grimaces">grimacing</span>, <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>, <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>, rhythmic protrusion of tongue, bulbar type of speech, <span class="product-label-link" type="condition" conceptid="4339090" conceptname="Trismus">trismus</span>, <span class="product-label-link" type="condition" conceptid="4313849" conceptname="Opisthotonus">opisthotonus</span> (<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>-like reactions), and rarely, <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span> and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> possibly due to <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>; ordinarily these symptoms are readily reversed by diphenhydramine [see <a href="#b1b755f1-974a-4b63-acb7-6e0978df78c5">Warnings and Precautions (5.1)</a>].</p>
<p>Drug-induced Parkinsonian-like symptoms may include <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">bradykinesia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4208094" conceptname="Cogwheel muscle rigidity">cogwheel rigidity</span>, mask-like facies [see <a href="#ba2509aa-6714-460d-868f-75ad26764e72">Warnings and Precautions (5.2)</a>].</p>
<p><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive dyskinesia</span> is most frequently characterized by involuntary movements of the tongue, face, mouth, or jaw, and sometimes by involuntary movements of the trunk and/or extremities; movements may be choreoathetotic in appearance. <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Motor restlessness</span> (<span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>) may include inability to sit still, pacing, and foot tapping. These symptoms may disappear spontaneously or respond to a reduction in dosage.</p>
<p><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span>: Rare occurrences of <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) have been reported [see <a href="#b07f7405-02c0-4ecd-8ccd-4e8aeb3aa2b8">Warnings and Precautions (5.3)</a>].</p>
<p>Endocrine Disturbances: <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">Galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> secondary to <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span>. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> secondary to transient elevation of aldosterone.</p>
<p>Cardiovascular: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, possible <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>.</p>
<p>Gastrointestinal: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, bowel disturbances, primarily <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>Hepatic: Rarely, cases of hepatotoxicity characterized by such findings as <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and altered liver function tests, when metoclopramide was administered with other drugs with known hepatotoxic potential.</p>
<p>Renal: <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary frequency</span> and <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>.</p>
<p>Hematologic: A few cases of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, or <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, generally without clear-cut relationship to metoclopramide. <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span> in adults and especially with overdosage in neonates. <span class="product-label-link" type="condition" conceptid="4137763" conceptname="Sulfhemoglobinemia">Sulfhemoglobinemia</span> in adults.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span>: A few cases of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, especially in patients with a history of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. Rarely, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, including glossal or <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>.</p>
<p>Miscellaneous: <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual disturbances</span>. <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">Porphyria</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1><span class="Bold">7Â  DRUG INTERACTIONS 
</span></h1>
<p class="First">The effects of metoclopramide on gastrointestinal motility can impact the absorption of other drugs. The known drug-drug interactions are listed below.</p>
<div class="Section">
<a name="bd8dd417-8ca1-4e71-acc1-b11606c15f6b"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold">7.1 Anticholinergic and Narcotic Analgesic Drugs
</span></h2>
<p class="First">The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.</p>
</div>
<div class="Section">
<a name="b54eabae-27bd-4b39-8473-45e0db38c7f3"></a><a name="section-7.2"></a><p></p>
<h2><span class="Bold">7.2 Monoamine Oxidase Inhibitors
</span></h2>
<p class="First">Metoclopramide has been shown to release catecholamines in patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> suggesting that it should be used cautiously, if at all, in patients taking monoamine oxidase (MAO) inhibitors.</p>
</div>
<div class="Section">
<a name="b62e1014-59ad-46e9-bf9d-e44956a52a6c"></a><a name="section-7.3"></a><p></p>
<h2><span class="Bold">7.3 Drug Absorption
</span></h2>
<p class="First">Absorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin), whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).</p>
</div>
<div class="Section">
<a name="b72733d6-624f-4b49-8323-6d4bb402780a"></a><a name="section-7.4"></a><p></p>
<h2><span class="Bold">7.4 Insulin
</span></h2>
<p class="First">Because the action of metoclopramide will hasten the movement of food to the intestines and therefore the rate of absorption, insulin dosage or timing of dosage may require adjustment. Increasing movement of food to the intestines may lead to absorption of less glucose from a meal, hence less glucose in the circulation for a particular dose of administered insulin to act upon, resulting in <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
<div class="Section">
<a name="bec5902b-3504-4335-9fc1-67b48632afbf"></a><a name="section-7.5"></a><p></p>
<h2><span class="Bold">7.5 Antidepressants, Antipsychotics, and Neuroleptics
</span></h2>
<p class="First">Concomitant use of metoclopramide should be avoided in patients taking antidepressants, antipsychotics, and/or neuroleptics that have been associated with extrapyramidal reactions such as <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) that have occurred in association with metoclopramide [see <a href="#ba2509aa-6714-460d-868f-75ad26764e72">Warnings and Precautions (5.2)</a>, (<a href="#b07f7405-02c0-4ecd-8ccd-4e8aeb3aa2b8">5.3</a>) and <a href="#bf0ec9b7-d841-45aa-b9d0-45038b6d6837">Adverse Reactions (6.2)</a>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1><span class="Bold"> 8Â  USE IN SPECIFIC POPULATIONS 
</span></h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2><span class="Bold">8.1Â  Pregnancy
</span></h2>
<p class="First"><span class="Bold">Teratogenic Effects: Pregnancy Category B</span><span class="Bold"><br></span>Reproduction studies have been performed in rats at oral doses about 6 times the maximum recommended human dose calculated on the basis of surface area, and in rabbits at oral doses about 12 times the maximum recommended human dose calculated on the basis of surface area, and have revealed no evidence of impaired fertility or harm to the fetus due to metoclopramide. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-8.2"></a><p></p>
<h2><span class="Bold">8.2 Labor and Delivery
</span></h2>
<p class="First">The use of metoclopramide in labor and delivery has not been studied.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.3"></a><p></p>
<h2><span class="Bold">8.3 Nursing Mothers
</span></h2>
<p class="First">Metoclopramide is excreted in human milk. Caution should be exercised when metoclopramide is administered to a nursing mother. Because of the potential for serious adverse reactions from metoclopramide in nursing infants and because of the potential for tumorigenicity (including tumor promoting potential in rats), a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ba3e9d3a-79e6-41e5-b58e-14d5bbf418c5"></a><a name="section-8.4"></a><p></p>
<h2><span class="Bold">8.4 Pediatric Use
</span></h2>
<p class="First">The safety and effectiveness of Metoclopramide Hydrochloride Orally Disintegrating Tablets in pediatric patients have not been established.</p>
<p>The safety profile of Metoclopramide Hydrochloride Orally Disintegrating Tablets in adults cannot be extrapolated to pediatric patients. <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonias</span> and other extrapyramidal reactions associated with metoclopramide are more common in the pediatric population than in adults. In addition, neonates have reduced levels of NADH-cytochrome b5 reductase making them more susceptible to <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>, a possible side effect of metoclopramide use in neonates.</p>
<p><span class="Italics Underline">Pediatric PK</span><span class="Underline"><br></span>The pharmacodynamics of metoclopramide following oral and intravenous administration in pediatric populations are highly variable and a concentration-effect relationship has not been established. Thus, there are insufficient data to conclude whether the pharmacokinetics of Metoclopramide Hydrochloride Orally Disintegrating Tablets in adults and the pediatric population are similar. Although there are insufficient data to support the efficacy of metoclopramide in pediatric patients with symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) or cancer chemotherapy-related <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, the pharmacokinetics of metoclopramide have been studied in these patient populations and are summarized as follows.</p>
<p>In an open-label study, six pediatric patients (ranging in age from 3.5 weeks to 5.4 months) with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> received metoclopramide 0.15 mg/kg oral solution every 6 hours for 10 doses. The mean peak plasma concentration of metoclopramide after the tenth dose was twice the level (56.8 mcg/L) compared to after the first dose (29 mcg/L) indicating drug accumulation with repeated dosing. However, the PK parameters after the tenth dose were comparable to those observed after the first dose for the mean time to reach peak concentrations (2.2 hr); half-life (4.1 hr); clearance (0.67 L/h/kg); and volume of distribution (4.4 L/kg). The youngest patient (3.5 weeks) showed a significantly longer half-life after the first dose (23.1 hr) compared to after the tenth dose (10.3 hr), suggesting the reduced clearance observed at birth may be a reflection of the immature hepatic and renal systems.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="b6750a90-0c93-461a-96f0-95e9fff34c04"></a><a name="section-8.5"></a><p></p>
<h2><span class="Bold">8.5 Geriatric Use
</span></h2>
<p class="First">Clinical studies of metoclopramide did not include sufficient numbers of subjects aged 65 and over to determine whether elderly subjects respond differently from younger subjects.</p>
<p>The risk of developing drug-induced <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span> due to metoclopramide is dose-related. Geriatric patients should receive the lowest dose that is effective. If drug-induced <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span> symptoms develop in a geriatric patient, Metoclopramide Hydrochloride Orally Disintegrating Tablets should be discontinued. The elderly may be at greater risk for <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> [see <a href="#b1b755f1-974a-4b63-acb7-6e0978df78c5">Warnings and Precautions (5.1)</a>].</p>
<p>Sedation is a potential adverse event associated with metoclopramide use in the elderly.</p>
<p>Metoclopramide is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. For these reasons, dose selection for an elderly patient should be cautious, starting at the low end of the dosing range, due to the greater frequency of decreased renal function, concomitant disease, or other drug therapy in the elderly. [see <a href="#bc732cb4-4b83-4e29-8b11-21dfceff70f8">Warnings and Precautions (5.4)</a>].</p>
</div>
<div class="Section">
<a name="bf00df90-aa3f-4c27-935a-8329ab593f8a"></a><a name="section-8.6"></a><p></p>
<h2><span class="Bold">8.6 Other Special Populations
</span></h2>
<p class="First">Patients with NADH-cytochrome b5 reductase deficiency are at an increased risk of developing <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> and/or <span class="product-label-link" type="condition" conceptid="4137763" conceptname="Sulfhemoglobinemia">sulfhemoglobinemia</span> when metoclopramide is administered. In patients with G6PD deficiency who experience metoclopramide-induced <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>, methylene blue treatment is not recommended.</p>
<p>Since metoclopramide is excreted principally through the kidneys, therapy should be initiated at approximately one-half the recommended dose in those patients whose creatinine clearance is below 40 mL/min. Depending upon clinical efficacy and safety considerations, the dosage may be increased or decreased as appropriate. Metoclopramide has been safely used in patients with advanced liver disease whose renal function was normal.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1><span class="Bold">10Â  OVERDOSAGE 
</span></h1>
<p class="First">Symptoms of overdosage may include <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, and extrapyramidal reactions. Anticholinergic or anti-Parkinson drugs or antihistamines with anti-cholinergic properties may be helpful in controlling the extrapyramidal reactions. Symptoms are self-limiting and may disappear within 24 hours.</p>
<p>Hemodialysis removes relatively little metoclopramide, probably because of the small amount of the drug in blood relative to tissues. Similarly, continuous ambulatory peritoneal dialysis does not remove significant amounts of drug. It is unlikely that dosage would need to be adjusted to compensate for losses through dialysis. Dialysis is not likely to be an effective method of drug removal in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> situations.</p>
<p>Unintentional <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> has been reported in infants and children with the use of metoclopramide oral solution. While there was no consistent pattern to the reports associated with these <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>, events included <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, extrapyramidal reactions, and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span> has occurred in premature and full-term neonates who were given <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of metoclopramide (1 to 4 mg/kg/day orally, intramuscularly or intravenously for 1 to 3 or more days). <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span> can be reversed by the intravenous administration of methylene blue. However, methylene blue may cause <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> in patients with G6PD deficiency, which may be fatal.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1><span class="Bold">11Â  DESCRIPTION 
</span></h1>
<p class="First">Metoclopramide Hydrochloride Orally Disintegrating Tablet is an orally disintegrating tablet formulation of metoclopramide hydrochloride. The 5 mg strength tablets are round, white to off-white, flat faced beveled edge tablet debossed with â€˜Nâ€™ on one side and â€œ581â€? on the other side; it is comprised of 5 mg metoclopramide (as 5.91 mg of metoclopramide hydrochloride). The 10 mg tablets are round, white to off-white, flat faced beveled edge tablet debossed with â€˜Nâ€™ on one side and â€œ580â€? on the other side; it is comprised of 10 mg metoclopramide (as 11.82 mg of metoclopramide hydrochloride).</p>
<p>The active ingredient, metoclopramide hydrochloride, is a white crystalline, odorless substance, freely soluble in water. Chemically, it is 4 amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy benzamide monohydrochloride monohydrate. Its molecular formula is C<span class="Sub">14</span>H<span class="Sub">22</span>ClN<span class="Sub">3</span>O<span class="Sub">2</span>â€¢HClâ€¢H<span class="Sub">2</span>O. Its molecular weight is 354.3. The structural formula is shown in Figure 1.</p>
<p><span class="Underline">Figure 1</span></p>
<div class="Figure"><img alt="E:\Desktop\Labeling Response\Metoclopramide\metoclo-spl\ODT.JPG" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3fb9a45e-48ba-45c5-86a7-03a8744888f6&amp;name=e386144b-figure-01.jpg"></div>
<p>Metoclopramide Hydrochloride Orally Disintegrating Tablets includes the following inactive ingredients: phosphoric acid, mannitol and starch, microcrystalline cellulose, colloidal silicon dioxide, amino methacrylate copolymer, butylated hydroxyanisole, butylated hydroxytoluene, crospovidone, aspartame, N-C mint flavor, magnesium stearate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1><span class="Bold">12Â  CLINICAL PHARMACOLOGY 
</span></h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2><span class="Bold">12.1 Mechanism of Action
</span></h2>
<p class="First">Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. While its mode of action is unclear, it appears to sensitize tissues to the action of acetylcholine. The effect on motility is not dependent on intact vagal innervation, but can be abolished by anticholinergic drugs. Metoclopramide increases the tone and amplitude of gastric (especially antral) contractions, relaxes the pyloric sphincter and the duodenal bulb, and increases peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit. It increases the resting tone of the lower esophageal sphincter. It has little, if any, effect on the motility of the colon or gallbladder.</p>
<p>The antiemetic properties of metoclopramide appear to be a result of its antagonism of central and peripheral dopamine receptors. Dopamine produces <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> by stimulation of the medullary chemoreceptor trigger zone (CTZ), and metoclopramide blocks stimulation of the CTZ by agents like l-dopa or apomorphine, which are known to increase dopamine levels or to possess dopamine-like effects. Metoclopramide also abolishes the slowing of gastric emptying caused by apomorphine. Like the phenothiazines and related drugs, which are also dopamine antagonists, metoclopramide produces sedation and may produce extrapyramidal reactions [see <a href="#ba2509aa-6714-460d-868f-75ad26764e72">Warnings and Precautions (5.2)</a>, (<a href="#b07f7405-02c0-4ecd-8ccd-4e8aeb3aa2b8">5.3</a>)]. Metoclopramide inhibits the central and peripheral effects of apomorphine, induces release of prolactin, and causes a transient increase in circulating aldosterone levels, which may be associated with transient <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2><span class="Bold">12.2 Pharmacodynamics
</span></h2>
<p class="First">The onset of pharmacological action of metoclopramide is 30 to 60 minutes following an oral dose; pharmacological effects persist for 1 to 2 hours. In patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span> and low LESP (lower esophageal sphincter pressure), single oral doses of metoclopramide produce dose-related increases in LESP. Effects begin at about 5 mg and increase through 20 mg (the largest dose tested). The increase in LESP from a 5 mg dose lasts about 45 minutes and that of a 20 mg dose lasts between 2 and 3 hours. Increased rate of stomach emptying has been observed with single oral doses of 10 mg.</p>
<p>The principal effect of metoclopramide is on symptoms of post-prandial and daytime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulcers</span> and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg taken four times a day.</p>
<p>As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. For <span class="product-label-link" type="condition" conceptid="195847" conceptname="Gastroparesis syndrome">gastroparesis</span>, the usual manifestations of <span class="product-label-link" type="condition" conceptid="4010028" conceptname="Impaired gastric emptying">delayed gastric emptying</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, persistent fullness after meals, and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>) appear to respond within different time intervals.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="b07d20d6-23ef-4402-95d4-adb7f0dc21dd"></a><a name="section-11.3"></a><p></p>
<h2><span class="Bold">12.3 Pharmacokinetics
</span></h2>
<p class="First"><span class="Italics Underline">Adult PK of Metoclopramide Hydrochloride Orally Disintegrating Tablets</span></p>
<p>In a randomized, two-arm, two-way crossover study in 44 healthy adult (male and female) fasted subjects, Metoclopramide Hydrochloride Orally Disintegrating Tablet was bioequivalent to Reglan Tablets.</p>
<p>In a food-effect study with 28 subjects, Metoclopramide Hydrochloride Orally Disintegrating Tablets taken immediately after a high-fat meal had a 17% lower peak blood level than when taken after an overnight fast. The time to peak blood levels increased from about 1.75 hours under fasted conditions to 3 hours when taken immediately after a high-fat meal. The extent of metoclopramide absorbed (area under the curve) was comparable whether Metoclopramide Hydrochloride Orally Disintegrating Tablets was administered with or without food. The clinical effect of the decrease in peak plasma level if Metoclopramide Hydrochloride Orally Disintegrating Tablet is inadvertently taken with food is unknown.</p>
<p><span class="Italics Underline">Adult PK of Metoclopramide</span></p>
<p>Metoclopramide is rapidly and well absorbed. Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% Â± 15.5% as demonstrated in a crossover study of 18 subjects. Peak plasma concentrations occur at about 1 to 2 hr after a single oral dose. Similar time to peak is observed after individual doses at steady state. A single dose study of 12 subjects showed that the area under the drug concentration-time curve increases linearly with doses from 20 to 100 mg (results summarized in Table 2). Peak concentrations increase linearly with dose; time to peak concentrations remains the same; whole body clearance is unchanged; and the elimination rate remains the same. The average elimination half-life in individuals with normal renal function is 5 to 6 hr. Linear kinetic processes adequately describe the absorption and elimination of metoclopramide.</p>
<table frame="void" width="638">
<caption><span> Table 2: Adult Pharmacokinetic Data</span></caption>
<tbody class="Headless">
<tr class="First">
<td class="BotruleLruleRruleToprule" align="center" valign="top">Parameter</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">Value</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="center" valign="top">Vd (L/kg)</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">~ 3.5</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="center" valign="top">Plasma Protein Binding</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">~ 30%</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="center" valign="top">T Â½</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">5 to 6 hours</td>
</tr>
<tr class="Last">
<td class="BotruleLruleRruleToprule" align="center" valign="top">Oral Bioavailability</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">80% Â± 15.5%</td>
</tr>
</tbody>
</table>
<p>Approximately 85% of the radioactivity of an orally administered dose appears in the urine within 72 hr. Of the 85% eliminated in the urine, about half is present as free or conjugated metoclopramide.</p>
<p>The drug is not extensively bound to plasma proteins (about 30%). The whole body volume of distribution is high (about 3.5 L/kg) which suggests extensive distribution of drug to the tissues.</p>
<p>The in vivo disintegration time (time reported between placing the tablet on the tongue and it completely disintegrated into fine particles) was approximately one minute (with a range of 10 seconds to 14 minutes). In the two clinical trials (N = 96) with a mean Â± SD being 76.8 Â± 110.6 seconds and a median of 53.5 seconds.</p>
<p><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> affects the clearance of metoclopramide. In a study with patients with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, non-renal clearance, and increase in elimination half-life. The kinetics of metoclopramide in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> remained linear. The reduction in clearance as a result of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> suggests that reduction of maintenance dosage should be done to avoid drug accumulation.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1><span class="Bold">13Â  NONCLINICAL TOXICOLOGY 
</span></h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2><span class="Bold">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</span></h2>
<p class="First">A 77-week study was conducted in rats with oral doses up to 40 mg/kg/day (about 5 times the maximum recommended human dose on surface area basis). Metoclopramide elevates prolactin levels and the elevation persists during chronic administration. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescription of metoclopramide is contemplated in a patient with previously detected breast cancer. Although disturbances such as <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> have been reported with prolactin-elevating drugs, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of prolactin-stimulating neuroleptic drugs and metoclopramide. Neither clinical studies nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is too limited to be conclusive at this time.</p>
<p>In a rat model for assessing the tumor promotion potential, a two-week oral treatment with metoclopramide at a dose of 260 mg/kg/day (about 35 times the maximum recommended human dose based on body surface area) enhanced the tumorigenic effect of N-nitrosodiethylamine.</p>
<p>Metoclopramide was positive in the in vitro Chinese hamster lung cell / HGPRT forward mutation assay for mutagenic effects and the in vitro human lymphocyte chromosome aberration assay for clastogenic effects. It was negative in the in vitro Ames mutation assay, the in vitro unscheduled DNA synthesis (UDS) assay with rat and human hepatocytes and the in vivo rat micronucleus assay.</p>
<p>Metoclopramide at intramuscular doses up to 20 mg/kg/day (about 3 times the maximum recommended human dose based on body surface area) was found to have no effect on fertility and reproductive performance of male and female rats.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-13"></a><p></p>
<h1><span class="Bold">16 HOW SUPPLIED/STORAGE AND HANDLING
</span></h1>
<p class="First">Metoclopramide Hydrochloride Orally Disintegrating Tablets 5 mg strength are round, white to off-white, flat faced beveled edge tablet debossed with â€˜Nâ€™ on one side and â€œ581â€? on the other side; it is comprised of 5 mg metoclopramide (as 5.91 mg of metoclopramide hydrochloride). These are packaged in <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards as follows:</p>
<p>Box of 10 (10x10s)Â Â  NDC 40032-581-30<br></p>
<p>Metoclopramide Hydrochloride Orally Disintegrating Tablets 10 mg are round, white to off-white, flat faced beveled edge tablet debossed with â€˜Nâ€™ on one side and â€œ580â€? on the other side; it is comprised of 10 mg metoclopramide (as 11.82 mg of metoclopramide hydrochloride). These are packaged in <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards as follows:</p>
<p>Box of 10 (10x10s)Â Â  NDC 40032-580-30</p>
<p><br>Tablets should be stored at controlled room temperature, between 20Â°C and 25Â°C (68Â°F and 77Â°F).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-14"></a><p></p>
<h1><span class="Bold">17Â  PATIENT COUNSELING INFORMATION
</span></h1>
<ul class="Disc">
<li>Instruct patients to take Metoclopramide Hydrochloride Orally Disintegrating Tablets at least 30 minutes before eating and at bedtime.</li>
<li>A patient Medication Guide is available for Metoclopramide Hydrochloride Orally Disintegrating Tablets and printed at the end of the prescribing information. Instruct patients, families, and caregivers to read the Medication Guide and assist them in understanding its contents.</li>
<li>Inform patients or their caregivers of serious potential issues associated with metoclopramide use such as <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, and <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>. Advise patients to inform their physician if symptoms associated with these disorders occur during or after treatment with Metoclopramide Hydrochloride Orally Disintegrating Tablets.</li>
<li>Inform patients that Metoclopramide Hydrochloride Orally Disintegrating Tablets may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or otherwise impair mental alertness or physical abilities required for the performance of hazardous tasks such as operating machinery or driving a motor vehicle. Sedation may be more pronounced in the elderly.</li>
<li>Inform patients that the most common adverse reactions in patients treated with Metoclopramide Hydrochloride Orally Disintegrating Tablets or other metoclopramide-containing products are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>.</li>
</ul>
<p class="First">Manufactured by:<br>Novel Laboratories, Inc.<br>Somerset, NJ 08873<br>USA<br>PI5800000101 Iss. 01/2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
</span></h1>
<p class="First">NDC 40032-580-30<br><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack<br>Metoclopramide Hydrochloride Orally Disintegrating Tablets<br>10 mg<br><br><img alt="e386144b-figure-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3fb9a45e-48ba-45c5-86a7-03a8744888f6&amp;name=e386144b-figure-02.jpg"></p>
<p>NDC 40032-580-30<br>Carton<br>Metoclopramide Hydrochloride Orally Disintegrating Tablets<br>10 mg</p>
<div class="Figure"><img alt="carton-10mg.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3fb9a45e-48ba-45c5-86a7-03a8744888f6&amp;name=e386144b-figure-03.jpg"></div>
<p>NDC 40032-581-30<br><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack<br>Metoclopramide Hydrochloride Orally Disintegrating Tablets<br>5 mg</p>
<div class="Figure"><img alt="e386144b-figure-04" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3fb9a45e-48ba-45c5-86a7-03a8744888f6&amp;name=e386144b-figure-04.jpg"></div>
<p>NDC 40032-581-30<br>Carton<br>Metoclopramide Hydrochloride Orally Disintegrating Tablets<br>5 mg</p>
<div class="Figure"><img alt="carton-5mg.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3fb9a45e-48ba-45c5-86a7-03a8744888f6&amp;name=e386144b-figure-05.jpg"></div>
<p><span class="Bold Underline">Medication Guide</span><span class="Bold"><br></span><span class="Bold">Metoclopramide Hydrochloride Orally Disintegrating Tablets</span></p>
<p><span class="Bold">Phenylketonurics:</span></p>
<p>Phenylalanine is a component of aspartame. Each 5 mg and 10 mg Metoclopramide Hydrochloride Orally Disintegrating Tablets contains 4.7 mg of phenylalanine.</p>
<p>Read the Medication Guide that comes with Metoclopramide Hydrochloride Orally Disintegrating Tablets before you take it and each time you get a refill. There may be new information. If you take another product that contains metoclopramide (such as REGLAN tablets, REGLAN ODT, REGLAN injection or metoclopramide oral solution), you should read the Medication Guide that comes with that product. Some of the information may be different. This Medication Guide does not take the place of talking with your doctor about your medical condition or your treatment.</p>
<p><span class="Bold">What is the most important information I should know about Metoclopramide Hydrochloride Orally Disintegrating Tablets?</span></p>
<p>Metoclopramide Hydrochloride Orally Disintegrating Tablets can cause serious side effects, including:</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span> (abnormal muscle movements)</span> These movements happen mostly in the face muscles. You cannot control these movements. They may not go away even after stopping Metoclopramide Hydrochloride Orally Disintegrating Tablets. There is no treatment for <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, but symptoms may lessen or go away over time after you stop taking Metoclopramide Hydrochloride Orally Disintegrating Tablets.</p>
<p>Your chances for getting <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> go up:</p>
<ul class="Disc">
<li>the longer you take Metoclopramide Hydrochloride Orally Disintegrating Tablets and the more Metoclopramide Hydrochloride Orally Disintegrating Tablets you take. You should not take Metoclopramide Hydrochloride Orally Disintegrating Tablets for more than 12 weeks.</li>
<li>if you are older, especially if you are an older woman</li>
<li>if you have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></li>
</ul>
<p>It is not possible for your doctor to know if you will get <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> if <span class="Bold">you</span> take Metoclopramide Hydrochloride Orally Disintegrating Tablets.</p>
<p>Call your doctor right away if you have movements you can not stop or control, such as:</p>
<ul class="Disc">
<li>lip smacking, chewing, or puckering of your lips</li>
<li>frowning or scowling</li>
<li>sticking out your tongue</li>
<li>blinking and moving your eyes</li>
<li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> of your arms and legs</li>
</ul>
<p>See the section â€œWhat are the possible side effects of Metoclopramide Hydrochloride Orally Disintegrating Tablets?â€? for more information about side effects.</p>
<p><span class="Bold">What is Metoclopramide Hydrochloride Orally Disintegrating Tablets?</span></p>
<p>Metoclopramide Hydrochloride Orally Disintegrating Tablets is a prescription medicine used in adults:</p>
<ul class="Disc">
<li>for 4 to 12 weeks to relieve <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> symptoms of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) when certain other treatments do not work.</li>
<li>to relieve the symptoms of slow stomach emptying in people with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</li>
</ul>
<p>It is not known if Metoclopramide Hydrochloride Orally Disintegrating Tablets is safe or works in children.</p>
<p><span class="Bold">Who should not take Metoclopramide Hydrochloride Orally Disintegrating Tablets?</span></p>
<p>Do not take Metoclopramide Hydrochloride Orally Disintegrating Tablets if you:</p>
<ul class="Disc">
<li>have stomach or intestine problems that could get worse with Metoclopramide Hydrochloride Orally Disintegrating Tablets, such as <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, blockage or a tear in your stomach or bowel wall</li>
<li>have an adrenal tumor called <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span></li>
<li>are allergic to metoclopramide or any of the ingredients in Metoclopramide Hydrochloride Orally Disintegrating Tablets. See the end of this Medication Guide for a list of ingredients in Metoclopramide Hydrochloride Orally Disintegrating Tablets.</li>
<li>take medicines that can cause uncontrolled movements, such as medicines for mental illness.</li>
<li>have <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></li>
</ul>
<p><span class="Bold">What should I tell my doctor before taking Metoclopramide Hydrochloride Orally Disintegrating Tablets?</span></p>
<p>Before you take Metoclopramide Hydrochloride Orally Disintegrating Tablets, tell your doctor if you:</p>
<ul class="Disc">
<li>have kidney or liver disease</li>
<li>have <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or mental illness</li>
<li>have high blood pressure</li>
<li>have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or heart rhythm problems</li>
<li>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Your dose of insulin may need to be changed.</li>
<li>have Parkinsonâ€™s disease</li>
<li>have any other medical conditions</li>
<li>drink alcohol</li>
<li>are pregnant or plan to become pregnant. It is not known if Metoclopramide Hydrochloride Orally Disintegrating Tablets will harm your unborn baby.</li>
<li>are breast-feeding or plan to breast-feed. Metoclopramide Hydrochloride Orally Disintegrating Tablets can pass into your milk and may harm your baby. You and your doctor should decide if you will take Metoclopramide Hydrochloride Orally Disintegrating Tablets or breast-feed. You should not do both.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.</span> Metoclopramide Hydrochloride Orally Disintegrating Tablets and some medicines can affect each other and may not work as well, or cause possible side effects. Do not start any new medicine while taking Metoclopramide Hydrochloride Orally Disintegrating Tablets until you talk with your doctor.</p>
<p><span class="Bold">Especially tell your doctor if you take:</span></p>
<ul class="Disc">
<li>another medicine that contains metoclopramide, such as REGLAN tablets, REGLAN ODT, or metoclopramide oral syrup</li>
<li>a blood pressure medicine</li>
<li>a medicine for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, especially a monoamine oxidase inhibitor (MAOI)</li>
<li>an anti-<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> medicine</li>
<li>insulin</li>
<li>medicines that can make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>, such as anti-<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> medicines, sleep medicines, and narcotics.</li>
</ul>
<p>Ask your doctor or pharmacist if you are not sure if your medication is listed above. Know the medicines you take. Keep a list of your medicines to show your doctor and pharmacist when you get new medicine.</p>
<p><span class="Bold">How should I take Metoclopramide Hydrochloride Orally Disintegrating Tablets?</span></p>
<ul class="Disc">
<li>Metoclopramide Hydrochloride Orally Disintegrating Tablets comes as a tablet that melts in your mouth.</li>
<li>Take Metoclopramide Hydrochloride Orally Disintegrating Tablets exactly as prescribed by your doctor. Do not change your dose unless your doctor tells you to.</li>
<li>You should not take Metoclopramide Hydrochloride Orally Disintegrating Tablets for more than 12 weeks.</li>
<li>Take Metoclopramide Hydrochloride Orally Disintegrating Tablets at least 30 minutes before eating and at bedtime.</li>
</ul>
<p>To take Metoclopramide Hydrochloride Orally Disintegrating Tablets:</p>
<ol class="Arabic">
<li>Leave the tablet in the sealed <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> Metoclopramide Hydrochloride Orally Disintegrating Tablets pack until you are ready to take it.</li>
<li>Use dry hands to open a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> and take out a tablet. If the tablet breaks or crumbles throw it away and take a new tablet out of the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack.</li>
<li>Put the tablet on your tongue right away. Let it melt and then swallow. You do not need water to take Metoclopramide Hydrochloride Orally Disintegrating Tablets.</li>
</ol>
<p>If you take too much Metoclopramide Hydrochloride Orally Disintegrating Tablets, call your doctor or Poison Control Center.</p>
<p><span class="Bold">What should I avoid while taking Metoclopramide Hydrochloride Orally Disintegrating Tablets?</span></p>
<ul class="Disc">
<li>Do not drink alcohol while taking Metoclopramide Hydrochloride Orally Disintegrating Tablets. Alcohol may make some side effects of Metoclopramide Hydrochloride Orally Disintegrating Tablets worse, such as feeling <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>.</li>
<li>Do not drive, work with machines, or do dangerous tasks until you know how Metoclopramide Hydrochloride Orally Disintegrating Tablets affects you. Metoclopramide Hydrochloride Orally Disintegrating Tablets may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>.</li>
</ul>
<p><span class="Bold">What are the possible side effects of Metoclopramide Hydrochloride Orally Disintegrating Tablets?</span></p>
<p><span class="Bold">Metoclopramide Hydrochloride Orally Disintegrating Tablets can cause serious side effects, including:</span></p>
<ul class="Disc">
<li>
<span class="Bold">Tardive</span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span> (abnormal muscle movements)</span> See â€œWhat is the most important information I should know about Metoclopramide Hydrochloride Orally Disintegrating Tablets?â€?</li>
<li>
<span class="Bold">Uncontrolled <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> of your face and neck muscles, or muscles of your body, arms, and legs (<span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>).</span> These <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span> can cause abnormal movements and body positions. These <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> usually start within the first 2 days of treatment. These <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> happen more often in children and adults younger than 30.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.</span> Some people who take Metoclopramide Hydrochloride Orally Disintegrating Tablets may become depressed. You may have thoughts about hurting or killing yourself. Some people who have taken metoclopramide products have ended their own lives (<span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>).</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS).</span> NMS is a rare but very serious condition that can happen with Metoclopramide Hydrochloride Orally Disintegrating Tablets. NMS can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and must be treated in a hospital. Symptoms of NMS include: high <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, stiff muscles, problems thinking, very fast or uneven heartbeat, and increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span>.</span> Symptoms include slight <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>, body <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>, trouble moving or keeping your balance. If you have Parkinsonâ€™s Disease, your symptoms may become worse while you are taking Metoclopramide Hydrochloride Orally Disintegrating Tablets.</li>
<li>
<span class="Bold">High blood pressure.</span> Metoclopramide Hydrochloride Orally Disintegrating Tablets can cause your blood pressure to increase.</li>
<li>
<span class="Bold">Too much body water.</span> People who have certain liver problems or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and take Metoclopramide Hydrochloride Orally Disintegrating Tablets may hold too much water in their body (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>). Tell your doctor right away if you have sudden <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your hands, legs, or feet.</li>
</ul>
<p><span class="Bold">Call your doctor and get medical help right away if you:</span></p>
<ul class="Disc">
<li>feel depressed or have thoughts about hurting or killing yourself</li>
<li>have high <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, stiff muscles, problems thinking, very fast or uneven heartbeat, and increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></li>
<li>have muscle movements you cannot stop or control</li>
<li>have muscle movements that are new or unusual</li>
</ul>
<p><span class="Bold">The most common side effects of Metoclopramide Hydrochloride Orally Disintegrating Tablets are:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span></li>
</ul>
<p>You may have more side effects the longer you take Metoclopramide Hydrochloride Orally Disintegrating Tablets and the more Metoclopramide Hydrochloride Orally Disintegrating Tablets you take.</p>
<p>You may still have side effects after you stop Metoclopramide Hydrochloride Orally Disintegrating Tablets. You may have symptoms from stopping (withdrawal) Metoclopramide Hydrochloride Orally Disintegrating Tablets such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and feeling dizzy or nervous.</p>
<p>Tell your doctor about any side effects that bother you or do not go away. These are not all the possible side effects of Metoclopramide Hydrochloride Orally Disintegrating Tablets.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1â€“800â€“FDA-1088.</p>
<p><span class="Bold">How do I store Metoclopramide Hydrochloride Orally Disintegrating Tablets?</span></p>
<ul class="Disc">
<li>Store Metoclopramide Hydrochloride Orally Disintegrating Tablets at room temperature, between 68Â°F to 77Â°F (20Â°C to 25Â°C).</li>
<li>Keep Metoclopramide Hydrochloride Orally Disintegrating Tablets away from moisture.</li>
<li>Throw away any Metoclopramide Hydrochloride Orally Disintegrating Tablets that is not used.</li>
</ul>
<p><span class="Bold">Keep Metoclopramide Hydrochloride Orally Disintegrating Tablets and all medicines away from children.</span></p>
<p><span class="Bold">General information about Metoclopramide Hydrochloride Orally Disintegrating Tablets</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Metoclopramide Hydrochloride Orally Disintegrating Tablets for a condition for which it was not prescribed. Do not give Metoclopramide Hydrochloride Orally Disintegrating Tablets to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about Metoclopramide Hydrochloride Orally Disintegrating Tablets. If you would like more information about Metoclopramide Hydrochloride Orally Disintegrating Tablets, talk with your doctor. You can ask your doctor or pharmacist for information about Metoclopramide Hydrochloride Orally Disintegrating Tablets that is written for health professionals.</p>
<p><span class="Bold">What are the ingredients in Metoclopramide Hydrochloride Orally Disintegrating Tablets?</span></p>
<p>Active ingredients: metoclopramide hydrochloride<br>Inactive ingredients: phosphoric acid, mannitol and starch, microcrystalline cellulose, colloidal silicon dioxide, amino methacrylate copolymer, butylated hydroxyanisole, butylated hydroxytoluene, crospovidone, aspartame, N-C mint flavor, magnesium stearate.</p>
<p>Novel Laboratories, Inc.<br>Somerset, NJ 08873<br>USA<br>PI5800000101 Iss. 01/2014</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METOCLOPRAMIDE HYDROCHLORIDEÂ 		
					</strong><br><span class="contentTableReg">metoclopramide hydrochloride tablet, orally disintegrating</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:40032-580</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METOCLOPRAMIDE HYDROCHLORIDE</strong> (METOCLOPRAMIDE) </td>
<td class="formItem">METOCLOPRAMIDE</td>
<td class="formItem">10Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PHOSPHORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYLATED HYDROXYANISOLE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYLATED HYDROXYTOLUENE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ASPARTAME</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">N;580</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:40032-580-30</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202191</td>
<td class="formItem">08/15/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METOCLOPRAMIDE HYDROCHLORIDEÂ 		
					</strong><br><span class="contentTableReg">metoclopramide hydrochloride tablet, orally disintegrating</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:40032-581</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METOCLOPRAMIDE HYDROCHLORIDE</strong> (METOCLOPRAMIDE) </td>
<td class="formItem">METOCLOPRAMIDE</td>
<td class="formItem">5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PHOSPHORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYLATED HYDROXYANISOLE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYLATED HYDROXYTOLUENE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ASPARTAME</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">N;581</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:40032-581-30</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202191</td>
<td class="formItem">08/15/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Novel Laboratories, Inc.
							(793518643)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Novel Laboratories, Inc. (793518643)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Novel Laboratories, Inc.</td>
<td class="formItem"></td>
<td class="formItem">793518643</td>
<td class="formItem">ANALYSIS(40032-580), MANUFACTURE(40032-580)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e386144b-3815-4770-8cb6-e7284219eb90</div>
<div>Set id: 3fb9a45e-48ba-45c5-86a7-03a8744888f6</div>
<div>Version: 5</div>
<div>Effective Time: 20140815</div>
</div>
</div>Â <div class="DistributorName">Novel Laboratories, Inc.</div></p>
</body></html>
